ADAPTIVE BIOTECHNOLOGIES CORPORATION Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $8.12 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-02-26
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $8.12, a 103.51% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $3.99, a 52.84% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $8.46, a 31.94% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $12.43, a 72.58% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $8.12, a 103.51% increase from fiscal 2024.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $3.99, a 52.84% decline from fiscal 2023.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $8.46, a 27.51% decline from fiscal 2022.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $11.67, a 70.37% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $8.12 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $8.12 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $8.12 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | $8.12 10-Q · filed 2025-05-01 | |||
| 2024-12-31 | $3.99 10-K · filed 2025-03-03 | |||
| 2024-09-30 | $3.99 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $3.99 10-Q · filed 2024-08-01 | |||
| 2024-03-31 | $3.99 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $8.46 10-K · filed 2024-02-29 | |||
| 2023-09-30 | $8.46 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $8.46 10-Q · filed 2023-08-02 | |||
| 2023-03-31 | $8.46 10-Q · filed 2023-05-03 | |||
| 2022-12-31 | $11.67 10-K · filed 2023-02-14 | |||
| 2022-09-30 | $11.67 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $11.66 10-Q · filed 2022-08-03 | |||
| 2022-03-31 | $12.43 10-Q · filed 2022-05-04 | |||
| 2021-12-31 | $39.39 10-K · filed 2022-02-15 | |||
| 2021-09-30 | $41.21 10-Q · filed 2021-11-03 | |||
| 2021-06-30 | $43.37 10-Q · filed 2021-08-04 | |||
| 2021-03-31 | $45.33 10-Q · filed 2021-05-05 | |||
| 2020-12-31 | $33.36 10-K · filed 2021-02-24 | |||
| 2020-09-30 | $31.98 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | $29.95 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | $29.68 10-Q · filed 2020-05-12 | |||
| 2019-12-31 | $9.72 10-K · filed 2020-02-26 | |||
| 2019-09-30 | $9.15 10-Q · filed 2019-11-12 | |||
| 2018-12-31 | $6.55 10-K · filed 2020-02-26 | |||
| 2017-12-31 | $6.27 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |